Introduction

The complement system is an important part of innate immunity which defends the host against infectious microorganisms, clears immune complexes (ICs) and dead cells, and serves as a bridge between the innate and adaptive immunity [1]. Complement can be activated through classical, alternative and mannose-binding lectin (MBL) pathways, each with different initiators (shown schematically in fig. 1).

The classical pathway is activated when C1q of C1 binds with high avidity to the Fc portion of immunoglobulin M (IgM; CH3 domain) or IgG (CH2 domain) in ICs.

Development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Cry-Ig, CR2-Cry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions.

Key Messages:

SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.

© 2015 S. Karger AG, Basel

Abstract

Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by loss of tolerance to self-antigens, the production of autoantibodies and deposition of complement-fixing immune complexes (ICs) in injured tissues. SLE is characterized by a wide range of clinical manifestations and targeted organs, with lupus nephritis being one of the most serious complications. The complement system consists of three pathways and is tightly controlled by a set of regulatory proteins to prevent injudicious complement activation on host tissue. The involvement of the complement system in the pathogenesis of SLE is well accepted; yet, its exact role is still not clear. Summary: Complement plays dual roles in the pathogenesis of SLE. On the one hand, the complement system appears to have protective features in that hereditary homozygous deficiencies of classical pathway components, such as C1q and C4, are associated with an increased risk for SLE. On the other hand, IC-mediated activation of complement in affected tissues is clearly evident in both experimental and human SLE along with pathological features that are logical consequences of complement activation. Studies in genetically altered mice have shown that lack of complement inhibitors, such as complement factor H (CFH) or decay-accelerating factor (DAF) accelerates the development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Cry-Ig, CR2-Cry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions. Key Messages: SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.

© 2015 S. Karger AG, Basel

Key Words

Animal model · Complement · Lupus nephritis · Systemic lupus erythematosus · Therapy

© 2015 S. Karger AG, Basel

Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by loss of tolerance to self-antigens, the production of autoantibodies and deposition of complement-fixing immune complexes (ICs) in injured tissues. SLE is characterized by a wide range of clinical manifestations and targeted organs, with lupus nephritis being one of the most serious complications. The complement system consists of three pathways and is tightly controlled by a set of regulatory proteins to prevent injudicious complement activation on host tissue. The involvement of the complement system in the pathogenesis of SLE is well accepted; yet, its exact role is still not clear. Summary: Complement plays dual roles in the pathogenesis of SLE. On the one hand, the complement system appears to have protective features in that hereditary homozygous deficiencies of classical pathway components, such as C1q and C4, are associated with an increased risk for SLE. On the other hand, IC-mediated activation of complement in affected tissues is clearly evident in both experimental and human SLE along with pathological features that are logical consequences of complement activation. Studies in genetically altered mice have shown that lack of complement inhibitors, such as complement factor H (CFH) or decay-accelerating factor (DAF) accelerates the development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Cry-Ig, CR2-Cry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions. Key Messages: SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.
Besides Igs, C1q also binds and facilitates the removal of apoptotic cells, which provides it an important role in immune tolerance. The binding of C1q to its target triggers its conformational change and self-activation of C1r, followed by the activation of C1s [2]. Activated C1 cleaves both C4 and C2 to generate C4a/C4b and C2a/C2b. C4b2a acts as a C3 convertase which cleaves and activates C3.

The alternative pathway is spontaneously activated by a C3 conformation change, which occurs slowly but continuously to generate hydrolyzed C3 [C3(H2O)]. C3(H2O) then binds factor B in the fluid phase. Upon factor B’s cleavage by factor D (adipsin), an initial C3 convertase C3(H2O)Bb is formed, which can be stabilized by properdin and amplify itself to form C3bBb, the alternative pathway C3 convertase [1].

The binding of MBL to terminal carbohydrate groups on certain microbes leads to the activation of the MBL-associated serine proteases (MASP). Activated MASP cleaves C4 to C4a/C4b and C4b. Immobilized C4b induces the binding of C2 which is also cleaved by MASP and generates the C4b2a C3 convertase [1].

Irrespective of the pathway of activation, cleavage of C3 and C5 ultimately occurs, with the generation of the C3a and C5a anaphylatoxins, C3b opsonins and C5b to start the nonenzymatic assembly of the C5b-9 membrane attack complex, which can result in cellular death or activation after membrane insertion [3].

To prevent injury to host tissues, complement activation is strictly regulated by a number of plasma and cell membrane-associated proteins (fig. 1) [1]. Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein, which binds C3b and C4b and accelerates the decay of C3 (C4b2a in classical pathway and C3bBb in alternative pathway) and C5 (C4b2a3b in classical pathway and C3bBb3b in alternative pathway) convertases [4]. CR1 is a single-chain transmembrane glycoprotein which has the combined functions of DAF and membrane cofactor protein (MCP). It accelerates the decay of C3 and C5 convertases like DAF, and it also serves as a cofactor for factor I-mediated inactivation of C3b and C4b into iC3b and iC4b like MCP [5].

The plasma proteins C4bp and complement factor H (CFH) also have cofactor activity for factor I-mediated inactivation of plasma C4b and C3b in the classical and alternative pathways, respectively. Specific to rodents is the 65-kDa rodent complement regulatory protein, more commonly referred to as CR1-related gene/protein y (Crry) which has combined decay-accelerating and factor I cofactor activity for C3b and C4b, similar to CR1 [6]. Lastly, at either ‘end’ of the complement cascades are C1 inhibitor (C1-INH) and CD59, which inhibit C1 activation and C5b-9 formation, respectively [7, 8].

The involvement of the complement system in the pathogenesis of a number of autoimmune diseases including systemic lupus erythematosus (SLE) is well accepted, yet its exact role is still not clear. On the one hand, hereditary deficiencies of early classical pathway complement components predispose patients to SLE. On the other hand, activation of complement by ICs is certainly a prominent feature in SLE that promotes tissue injury. There-
fore, an imbalance of the complement system in either direction and the respective roles of the classical and alternative pathways can have complex effects on the disease phenotype. The current review will discuss the dual roles of complement in SLE, and in particular in lupus nephritis.

The Role of the Complement System in Human SLE

The pathogenic roles of complement activation in human SLE were indicated from years of clinical observations: low total complement hemolytic activity (CH50) and decreased C3 and C4 levels have been found in about 75% of SLE patients with focal nephritis and 90% in patients with diffuse nephritis [9]. Additionally, the co-localization of Ig isotypes IgG, IgA and IgM with C1q, C4 and C3 (and C5b-9; the so called ‘full house’ pattern) in the glomeruli is almost exclusively present in glomeruli of patients with lupus nephritis [10]. Finally, complement split products such as C3d and C5b-9 can also be detected in the urine of SLE patients [11].

While frequent mutations in CFH and CD46 (which encodes MCP) found in atypical hemolytic uremic syndrome (aHUS) are not associated with lupus nephritis, SLE patients carrying these mutations do have an earlier onset of lupus nephritis [12]. SLE patients with lymphopenia and neutropenia were found to have lower levels of DAF and CD59 on neutrophils, and SLE patients with anemia had lower expression of CD59 and CR1 on erythrocytes, and the expression is correlated with disease activity [13]. In neutrophils from SLE patients, IC downregulates the levels of CR1 transcripts, both directly and indirectly via inhibiting IFN-γ-induced CR1 expression, an example of how lupus activity affects CR1 expression [14]. Nonetheless, higher CR1 expression on SLE patient leukocytes indicates a better prognosis [15], while lower leukocyte MCP expression is associated with lupus remission [16]. These findings not only suggest the pivotal roles of the complement system in the pathogenesis of SLE, but may also potentially provide noninvasive markers for the disease activity.

Impaired IC handling plays an important role in the pathogenesis in lupus nephritis. Since the complement system is required at all steps of normal IC metabolism, any number of alterations can lead to pathological glomerular IC accumulation, particularly in conditions of IC excess, as in SLE. Studies have shown the association of SLE with low levels of CR1 on erythrocytes, a key site of binding and transferring IC to the mononuclear phagocyte system [17], suggesting that a defective erythrocyte/IC-clearing system may be related to SLE pathogenesis.

In contrast to the widespread belief that generation of complement activation products in kidney and other disease sites is proinflammatory, patients with homozygous deficiencies of the C1 proteins (C1q or C1r/s) or C4 have a high prevalence (>80%) of autoantibodies and SLE-like disease [18]. Successful treatment of C1q-deficient SLE patients with fresh frozen plasma or hematopoietic stem cell transplantation has also been reported [19, 20]. It is also noteworthy that in SLE patients, anti-C1q antibodies are associated with proliferative lupus nephritis, and its levels may indicate renal disease activity [21]. More recently, it was reported that in the presence of sera from individuals deficient in C1q, C4, C2 or C3, phagocytosis of apoptotic cells was decreased compared with studies using normal sera, indicating important roles of all these complement classical pathway components in clearance of apoptotic and necrotic cells [22]. Circulating cell-derived microparticles in patients with SLE carry more IgG, IgM and C1q, and IgG-bearing microparticles are associated with autoantibodies and complement activation [23]. Interestingly, in the very rare cases of homoygous deficiency of C3, the most critical protein that affects all three pathways of complement activation, there is no association with SLE [24].

Complement also plays important roles in thrombotic complications associated with SLE. The risk of thrombosis is particularly high in SLE patients with antiphospholipid autoantibodies (aPL). One explanation is that aPL-containing ICs bind to platelets which can subsequently activate the classical complement pathway, as supported by the fact that SLE patients have increased levels of C1q, C3d and C4d on their platelets, especially in patients with a history of venous thrombosis. Sera from SLE patients with aPL antibodies has a higher capacity to activate the classical pathway on heterologous platelets [25]. Though C1q and C4d deposition on platelets is not specific for SLE, this is associated with venous thrombosis [26]. One study also suggests that small dense HDL particles may activate the complement system and are related to subclinical atherosclerosis in SLE patients [27].

Studies of Complement in Experimental Lupus Models

Two of the best studied murine models that spontaneously develop lupus-like syndromes are the F1 cross between New Zealand Black and New Zealand White mice (NZB/W) and the MRL/MpJ-1Tnfrsf6+/pr/J (MRL/1pr) strain [28]. Similar to the female predominance in hu-
mans, only female NZB/W mice develop SLE. Both models have B cell hyperactivity, autoantibodies, hypocomplementemia, circulating and glomerular-bound ICs, and severe nephritis. As in humans, there is plenty of circumstantial evidence that complement activation is actively involved in the pathogenesis of glomerular disease in these mice. In early stages (4 and 5 months in MRL/lpr and NZB/W mice, respectively), granular deposition of mouse IgG, IgA, IgM and C3 is present largely in the mesangium, coincident with histopathology showing mesangial proliferation. As the disease progresses, there are glomerular capillary wall IC deposits, proliferation of intrinsic endothelial and mesangial cells, and infiltration with inflammatory cells. Eventually, crescent formation (more often in MRL/lpr mice) and glomerulosclerosis (more often in NZB/W mice) occur, and mice die of renal failure [28].

The manipulation of individual complement proteins through genetic techniques in lupus mouse strains and functional inhibition through the use of specific antibodies or antagonists have provided considerable insight into how complement is involved in this disease. Given that C3 is the common point connecting all three pathways in complement activation and is tightly regulated naturally, many of the studies in lupus mice have concentrated on activators and regulators of C3.

DAF is a ubiquitously expressed GPI-anchored membrane protein that inhibits C3 activation through all pathways by inhibiting formation and accelerating decay of the C3/C5 convertase [4]. The relevance of DAF to lupus is suggested by the fact that DAF-deficient MRL/lpr mice had exacerbated lymphoproliferation, anti-chromatin autoantibody production and dermatitis, particularly exacerbated lymphoproliferation, anti-chromatin expression and skin while Crry is not. The exacerbated dermatitis can be explained by the fact that DAF is strongly expressed in the skin while Crry is suggested by the fact that DAF-deficient MRL/lpr mice developed comparable lymphadenopathy, anti-chromatin autoantibodies to what is seen in the complement-sufficient mice, suggesting the spontaneous mortality in lupus mice is largely due to kidney disease, this translated into prolonged survival, while the underlying abnormal autoimmunity was not affected [33]. To make this complement inhibition more applicable to human SLE treatment, a recombinant soluble form of Crry (Crry-Ig) was also used in MRL/lpr mice. In chronic usage from early in the autoimmune disease until the end stage, inhibited complement activation by Crry-Ig ameliorated lupus nephritis [34]. Interestingly, transcript profiling experiments showed that excessive matrix components such as collagens I, III, IV and VI were overexpressed in control MRL/lpr mice, which could be suppressed by complement inhibition with Crry-Ig. Potential explanations for these phenomena include Crry-Ig-mediated reductions in connective tissue growth factor and TGF-β1 expression, suggesting these profibrotic mediators are downstream of complement-induced injury and contribute to the progressive glomerulosclerosis in MRL/lpr mice [35].

In both human and experimental SLE, CR1/CR2 expression decreases over time, suggesting that this plays a role in disease [36, 37]. Yet, MRL/lpr mice deficient in CR1/CR2 had significantly lower levels of total IgG3 and specific IgG3 rheumatoid factor, supporting the role of CR1/CR2 in the production of IgG3 in response to autoantigens. Nonetheless, this decrease of IgG3 autoantibodies did not lead to a reduction in features of lupus nephritis [38].

C4bp is a major soluble complement inhibitor of the classical pathway. Elevated serum levels of C4bp in SLE patients suggested its involvement in this disease [39]. More detailed studies addressing this possibility were performed by the Braun group, using a C4bp-deficient MRL/lpr mouse model. While serum C4 levels are lower in MRL/lpr mice compared with normal C57BL/6 mice,

[6]. Given that the Crry-deficient mice generated by Xu et al. [31] have complete embryonic lethality from unrestricted maternal complement activation, a straightforward Crry-deficient murine lupus model is not available. The critical role of Crry in regulating complement in the kidney came from our study of transplantation of Crry−/−C3−/− kidneys into wild-type hosts. Due to the lack of Crry, there was marked inflammation in the tubulointerstitial which led to complete failure of the transplanted kidney within weeks (while the appropriate controls, including wild-type kidneys transplanted into wild-type or Crry−/−C3−/− mice remained normal) [32]. On the other hand, transgenic mice developed by our group that overexpressed a soluble form of Crry had less severe lupus nephritis as determined by BUN and albuminuria measurements when crossed into the MRL/lpr strain. Since the spontaneous mortality in lupus mice is largely due to kidney disease, this translated into prolonged survival, while the underlying abnormal autoimmunity was not affected [33]. To make this complement inhibition more applicable to human SLE treatment, a recombinant soluble form of Crry (Crry-Ig) was also used in MRL/lpr mice. In chronic usage from early in the autoimmune disease until the end stage, inhibited complement activation by Crry-Ig ameliorated lupus nephritis [34]. Interestingly, transcript profiling experiments showed that excessive matrix components such as collagens I, III, IV and VI were overexpressed in control MRL/lpr mice, which could be suppressed by complement inhibition with Crry-Ig. Potential explanations for these phenomena include Crry-Ig-mediated reductions in connective tissue growth factor and TGF-β1 expression, suggesting these profibrotic mediators are downstream of complement-induced injury and contribute to the progressive glomerulosclerosis in MRL/lpr mice [35].

In both human and experimental SLE, CR1/CR2 expression decreases over time, suggesting that this plays a role in disease [36, 37]. Yet, MRL/lpr mice deficient in CR1/CR2 had significantly lower levels of total IgG3 and specific IgG3 rheumatoid factor, supporting the role of CR1/CR2 in the production of IgG3 in response to autoantigens. Nonetheless, this decrease of IgG3 autoantibodies did not lead to a reduction in features of lupus nephritis [38].

C4bp is a major soluble complement inhibitor of the classical pathway. Elevated serum levels of C4bp in SLE patients suggested its involvement in this disease [39]. More detailed studies addressing this possibility were performed by the Braun group, using a C4bp-deficient MRL/lpr mouse model. While serum C4 levels are lower in MRL/lpr mice compared with normal C57BL/6 mice,
starting as early as 3 weeks of age (i.e. prior to autoimmune disease), surprisingly, deficiency of C4bp affected neither serum C4 levels nor the classical pathway hemolytic activity. With an unaffected complement classical pathway, C4bp deficiency did not lead to a significantly different outcome in these mice, which had similar amounts of glomerular C3 and IgG deposition, glomerulonephritis, tubulointerstitial inflammation, proteinuria and renal function. Moreover, the systemic immune response was not affected by the absence of C4bp in these mice [40]. One explanation for the negligible role of C4bp in lupus development in MRL/lpr mice is that the extensively activated classical pathway in this model simply overwhelms the absence of C4bp. In this situation, ‘a gain of function’ of C4bp may reveal more information as purified human C4bp successfully inhibited the classical complement pathway, leading to delayed or reduced disease development in these models [41].

In physiological situations, there is spontaneous continuous low-level alternative pathway activation that is restrained by effective complement regulation. While the traditional thinking is that SLE is induced through IC-directed classical pathway activation, the involvement of the alternative pathway has also been suggested in many studies. Gilkeson and colleagues demonstrated that complement factor B- or complement factor D-deficient MRL/lpr mice had reduced glomerular C3 deposition associated with less severe glomerular histopathology [42, 43]. These results imply that IC-directed classical pathway activation can recruit the potential alternative pathway to further amplify generation of C3 and C5 activation products. CFH-related protein C is absent in the circulation of MRL/lpr and NZB/W mice before and after the onset of lupus, implying that polymorphic variation may contribute to the development of SLE [44]. Our group demonstrated CFH-deficient MRL/lpr mice had significantly more albuminuria and higher BUN levels than MRL/lpr controls, which further led to earlier mortality. CFH-deficient MRL/lpr mice developed severe diffuse lupus nephritis by 12 weeks, with excessive interstitial infiltration of macrophages and neutrophils, and subendothelial and subepithelial immune deposits and extensive podocyte foot process effacement [45]. These findings indicate that loss of CFH accelerates the development of lupus nephritis and recapitulates the functional and structural features of human disease, distinct from the spontaneous disease in older CFH-deficient mice on mixed backgrounds [46].

C5b-9 deposition was found in diseased lupus kidneys more than 2 decades ago. Yet, compared with extensive studies focusing on C3 activation and its regulation, fewer studies have been done to investigate the downstream events following C3 activation in the pathogenesis of SLE. Wang et al. [47] used a specific monoclonal antibody to inhibit C5 function in NZB/W mice. Six months of continuous therapy led to a significantly delayed onset of proteinuria, improved renal pathological changes and prolonged survival, implicating a role of products of the terminal complement pathway, C5a and C5b-9, in lupus nephritis. On the other hand, CD59a-deficient MRL/lpr mice had exacerbated skin disease and lymphoproliferation through a complement-independent, autoimmune-regulatory mechanism, which is conferred by its expression on both bone marrow-derived cell and peripheral tissues [48].

The C3a and C5a anaphylatoxins are generated through complement activation when C3 and C5 are activated and cleaved. Increased expression of C3aR was found in glomeruli in human lupus nephritis [49]. C3aR and C5aR expression were significantly upregulated at both the mRNA and protein levels and accompanied by a wider cellular distribution in MRL/lpr mouse kidneys [50, 51]. This upregulated expression starts before the onset of kidney disease, supporting the possibility that they may be involved in the development of disease, rather than simply a consequence. Chronic administration of a specific C3aR antagonist (SB290157) led to significantly reduced kidney disease and prolonged survival in MRL/lpr mice [51]. Similarly, when C5a signaling was blocked in our studies with a specific antagonist [50] or in those by Wendeker et al. [52] through gene targeting, MRL/lpr mice animals displayed attenuated renal disease and prolonged viability. The effects of blocking C3aR and C5aR in lupus mice had certain features in common, including less renal neutrophil and macrophage infiltration, apoptosis and interleukin-1β expression [50, 51]. Effects on chemokine expression were distinct, with C3aR- and C5aR-inhibited MRL/lpr mice having reduced CCL5 (RANTES) and CXCL2 (MIP-2) expression, respectively. C3aR-inhibited mice also had increased phosphorylation of protein kinase B (Akt), which we considered suggestive that C3aR signals promote renal cell apoptosis through an Akt pathway [51]. In C5aR-deficient MRL/lpr mice, there was a reduction in CD4+ T cell renal infiltration, lower titers of anti-double-stranded DNA antibodies and inhibition of interleukin-12 p20 and IFN-γ production, suggesting that Th1 responses are important to link C5a signaling in lupus nephritis [52]. In contrast, C3aR-deficient MRL/lpr mice had elevated autoantibody titers, more glomerular crescents and more severe intrarenal vasculitis,
though this did not affect long-term renal injury or survival [53]. The mechanisms of different outcomes between the short-term (by using antagonist) and the long-term (by using gene targeting) blockade of C3aR signalling in this lupus model still need to be clarified. This may be due to the fact that the particular C3aR antagonist (SB290157) used in this study has a partial agonist activity as well [54].

Since C3 is the converging point for all three complement pathways, alterations in C3 activity through manipulating its regulators, such as Crry or DAF, or blockade of the effects of C3 activation with inhibitors of C3aR, C5aR or C5 have shown C3 activation is an important factor in the development of SLE. Surprisingly, C3 deficiency does not affect the development of nephritis in MRL/lpr mice, while glomerular IgG deposition is significantly increased [55]. This study is consistent with the important role of complement, and in particular C3, in the clearance of ICs [56]. The finding that homozygous deficiency of early components of the classical pathway other than C3 predisposes to SLE suggests that the physiological functions of these molecules are protective in SLE. While the exact mechanism is still unknown, studies found that mice with generated C1q and C4 deficiencies had impaired ability to clear apoptotic debris [57], leading to the accumulation of potentially immunogenic autoantigens and initiation of an autoimmune reaction in the right genetic setting. C1q-deficient mice had increased mortality and higher titers of autoantibodies, with 25% of the mice developing glomerulonephritis, characterized by glomerular IC deposits and apoptotic debris [58]. Further work suggests that C1q and DNaseI are important in the degradation of chromatin derived from necrotic cells [59]. It was also found that the IgG autoantibodies were responsible for the inhibition of macrophage removal of apoptotic cells through C3 deposition in MRL/lpr and NZB/W mice [60]. On the other hand, C3 deposition on nucleic acids is significantly reduced when dsDNA-specific IgG autoantibodies are present in the serum, which increase as disease progresses in MRL/lpr mice [61].

In both human and experimental lupus nephritis, the complement system has a dual role. The classic pathway contributes to its protective role in the clearance of apoptotic material and circulating IC [22, 62]. In theory, chronic systemic complement inhibition may increase circulating IC and exacerbate disease [34]. To selectively target the desired complement regulator to the site of tissue injury, Tomlinson and colleagues used CR2 as the ‘guide’ of complement inhibitors, given that sites of complement activation are ‘marked’ by the presence of C3d [63], and CR2 has natural affinity for C3d. Thus, low doses of chimeric CR2-DAF and CR2-CD59 efficiently protected target cells from complement attack [64]. CR2-DAF was targeted to the glomerulus in lupus nephritis while soluble DAF failed [64]. Long-term (8-week) treatment of diseased MRL/lpr mice with low doses of CR2-Crry and CR2-CFH provided significant complement inhibition locally in the lupus glomerulus, which conferred significant reduction of proteinuria, as well as prolonged survival in these mice [65, 66]. CR2-CFH also significantly reduced glomerulonephritis [66]. The fact that selective alternative pathway inhibition by CR2-CFH provided significant reduction in glomerulonephritis while total complement inhibition with CR2-Crry did not supports that the alternative and classical pathways of complement has distinct roles in the pathogenesis of lupus nephritis [66, 67].

Investigations of complement activation in lupus nephritis suggested not only potential therapies, but also diagnostic and monitoring tools. Using CR2-targeted MRI, glomerular C3b/iC3b/C3d deposition in MRL/lpr mice was found to increase with disease activity, suggesting its usage as a marker of onset and severity of lupus glomerulonephritis, which could be used to monitor the disease course and its response to therapy repeatedly and noninvasively [68].

What We Have Learned from Animals Can Be Used in the Treatment of Humans

Strategies to manipulate the complement system in different human diseases have followed from successful animal studies, including those using recombinant intrinsic complement regulators and blocking antibodies. In addition to the treatment approaches indicated in studies using experimental models discussed above, we will focus on several promising therapeutic approaches that have been used in the treatment of human diseases, and may potentially extend to the treatment of human SLE and lupus nephritis.

Soluble CR1 (sCR1) was first developed in 1990, and has both decay accelerator and cofactor activity in classical and alternative complement pathways. A current therapeutic form of soluble CR1 designated as TP10 (Avant Immunotherapeutics, Needham, Mass., USA) has been used in clinical trials in several human diseases, including acute respiratory distress syndrome [69], ischemia-reperfusion injury in patients undergoing lung transplantation [70] or cardiac surgery [71]. These studies showed that sCR1 was well tolerated, with low development of anti-
sCR1 antibodies [71]. More recently, soluble CR1 was found to prevent dysregulation of the alternative pathway C3 convertases in dense deposit disease and C3 glomerulonephritis (C3GN), supporting the clinical trial of soluble CR1 as a treatment for DDD and C3GN [72].

C1 esterase inhibitor (C1-INH) has been marketed as replacement therapy for hereditary angioedema (HAE) and ischemia-reperfusion injury. Plasma-derived C1-INH has shown to be effective in prophylaxis, reducing the frequency of attacks of HAE and shortening the duration of the acute attacks [73]. Recombinant human C1-INH also proved to be effective in the treatment of HAE patients during acute attacks [74]. C1-INH was also reported to successfully ameliorate both complement deposition on RBCs and hemolysis in autoimmune hemolytic anemia [75].

The most extensively used antibody targeting the complement system is a monoclonal antibody that directly binds human C5 and prevents its cleavage to C5a and C5b as a humanized monoclonal antibody (Eculizumab, Alexion Pharmaceuticals Inc., Cheshire, Conn., USA). In March 2007, Eculizumab (Soliris) was the first and the only US Food and Drug Administration (FDA)-approved complement inhibitor used in the treatment of human diseases. It was approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria, an acquired disorder of GPI-linked proteins including DAF and CD59 characterized by spontaneous complement activation and C5b-9-mediated hemolysis. It was subsequently approved for the treatment of aHUS in 2011. Different phase 3 clinical trials showed that eculizumab treatment showed better stabilization of hemoglobin and reduced intravascular hemolysis with significant clinical improvements [76] even with long-term treatment [77]. Eculizumab increases aHUS patients’ platelet count, with 80% of patients achieving thrombotic microangiopathic event-free status [78]. With this beneficial effect of eculizumab in aHUS, it is encouraging that a phase 1 trial has shown it is safe, with a prolonged interval of complement inhibition in SLE patients. Moving to the kidney, a multicenter phase 2 trial in the United States in which 122 patients with idiopathic membranous nephropathy were enrolled in a randomized placebo-controlled study of eculizumab has been completed. Unfortunately, there was no difference between treatment and placebo in the primary outcome variable of urinary protein excretion. Because of the short-term treatment strategy in a long-term disease, the study design may have been insufficient to uncover a true therapeutic effect. This is supported by the finding of an apparent benefit in patients enrolled in an open-label extension. Based on the impressive effects of long-term treatment with anti-C5 effects in lupus nephritis in NZB/W lupus mice [47], Furie’s group conducted a phase 1 study with eculizumab in 24 patients with lupus nephritis. In this single-center, randomized, placebo-controlled, double-blind, dose-ranging trial, patients were given a single intravenous dose of eculizumab or placebo and were followed for 2 months. Only mild adverse events were reported, and complement inhibition for 10 days in the 8 mg/kg group was observed [79]. We also designed a multicenter phase 2 trial using eculizumab in proliferative lupus nephritis supported by the United States’ National Institutes of Health. Unfortunately, after enrollment of our first patient, this study encountered logistical delays and ultimately came to a complete halt. While this reflects the difficulties in clinical trials for a disorder such as lupus nephritis, based on what is known about the pathophysiology, we remain interested in the potential efficacy of this drug in the treatment of lupus nephritis.

Disclosure Statement

There is no financial conflict of interest affecting any of the authors.

References


36 Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM: Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): Expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1999;159:1557–1569.


Complement in Lupus Nephritis


